title: [Plasma beta-glucan levels in deep fungal infections accompanying hematological diseases and clinical efficacy of miconazole--a multi-institutional study].
abstract: Miconazole (400-1200 mg/day) was administered to patients with deep mycosis and suspected deep mycosis, and the efficacy evaluated. beta-Glucan was determined as the early diagnostic parameter of deep mycosis, and the relationships between the clinical efficacy of miconazole and the titers of beta-glucan were also evaluated. Forty-nine cases were evaluated, including 2 cases of deep mycosis and 47 cases of suspected deep mycosis. Most of the patients had hematological malignancies. The rate of efficacy was 100% (2/2) in deep mycosis, 66.0% (31/47) in suspected deep mycosis, and 67.3% (33/49) in total. beta-Glucan was determined in 39 cases before the administration of miconazole. The rate of beta-glucan positivity was 100% (1/1) in deep mycosis and 44.7% (17/38) in suspected deep mycosis. beta-Glucan was also determined before and after the administration of miconazole in 11 cases. The titers of beta-glucan became negative in 6 cases, decreased in 2 cases and increased in 3 cases. Thus, the beta-glucan titers became negative or decreased in 72.7% (8/11) of the cases. Efficacy of miconazole was 83.3% (5/6) in the cases in which beta-glucan became negative, 50.0% (1/2) in the cases in which the titers of beta-glucan decreased, and 33.3% (1/3) in the cases in which the titers of beta-glucan increased. Miconazole was effective in the treatment of deep mycosis, and the titers of beta-glucan correlated well with the clinical efficacy of miconazole. The determination of beta-glucan appears to be useful for the diagnosis of deep mycosis.
authors.affiliation: Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo.
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: K
authors.initials: K
authors.lastname: Miyagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohbayashi
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: A
authors.initials: A
authors.lastname: Togawa
authors.forename: M
authors.initials: M
authors.lastname: Amano
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: T
authors.initials: T
authors.lastname: Nomura
authors.forename: K
authors.initials: K
authors.lastname: Dan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005936:Glucans / Q000097:blood*; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008297:Male; D008825:Miconazole / Q000627:therapeutic use*; D008875:Middle Aged; D009181:Mycoses / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D015415:Biomarkers; D005936:Glucans; D008825:Miconazole